Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States

BACKGROUND: We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective. METHODS: A partitioned survival model consisting of three health states, progression-free survival (PFS), progressive disease, and death, w...

Descripción completa

Detalles Bibliográficos
Autores principales: McCrea, Charles, Johal, Sukhvinder, Yang, Shuo, Doan, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810189/
https://www.ncbi.nlm.nih.gov/pubmed/29456880
http://dx.doi.org/10.1186/s40164-018-0095-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810189/
https://www.ncbi.nlm.nih.gov/pubmed/29456880
http://dx.doi.org/10.1186/s40164-018-0095-8

Ejemplares similares